A carregar...
Publicação
Probioxy: redefining the treatment landscape of inflammatory bowel disease - operations and key assets
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 979.98 KB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
ProbiOxy, a biopharmaceutical start-up, is committed to developing the first
probiotic treatment for Inflammatory Bowel Disease (IBD) to improve patients' quality of life.
Our strategic approach involves securing initial funding, licensing intellectual property,
advancing through pre-clinical and clinical trials, growing our patent portfolio, developing the
product pipeline, and ultimately achieving acquisition by a prominent pharmaceutical entity.
Central to our strategy is securing exclusive licensing of intellectual property from the Calouste
Gulbenkian Foundation, allowing comprehensive ownership and strategic partnerships
essential for market positioning. We prioritize protecting our intellectual property through
patent filings and ongoing innovation to establish a robust portfolio, enhancing our
competitiveness. Collaborations with Instituto Gulbenkian de Ciência and Contract Research
Organizations accelerate research and clinical trials, ensuring regulatory compliance and
market approval. Our diverse Board of Directors and Advisory Board drive innovation and
strategic growth, while investor representatives align our strategic direction with market
insights. Our financial strategy emphasizes securing venture capital investments to fuel research
and development, ensuring prudent financial management aligned with operational milestones.
ProbiOxy's dedication to compliance with regulatory standards, guided by partnerships with
regulatory and legal experts underpins our commitment to safety and innovation in the probiotic
sector. Through meticulous planning, strategic partnerships, and regulatory compliance,
ProbiOxy aim to position itself as a leader in revolutionizing intestinal inflammation treatment with probiotics.
Descrição
Palavras-chave
Probiotics Operations Assets Entrepreneurship